Fundz

Maia Biotechnology, Inc. Raises $8.0 Million Financing To Advance Pipeline Of Targeted Immuno-Oncology Studies

PUBLIC · MAIAMay 19, 2021

Amount Raised

$8 Million

Round Type

Funding Round

ChicagoBiotechnologyHealth CareScience And EngineeringMedicalTherapeutics

Description

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing first-in-class oncology drugs, today announced that it has raised $8.0 million financing in a convertible note offering led by new investor Checkmate Capital Group with participation from other strategic and existing investors. The proceeds of the financing will advance the company’s targeted immuno-oncology programs and will support the initiation of a Phase 1/2 clinical trial evaluating THIO followed by Libtayo® (cemiplimab) in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The Phase 1/2 clinical trial is expected to begin later this year.

Quick answer

MAIA Biotechnology raised $8 Million in a Funding Round round, dated May 19, 2021. MAIA Biotechnology is based in Chicago, Illinois, United States.

How much did MAIA Biotechnology raise?
MAIA Biotechnology raised $8 Million in a Funding Round round on May 19, 2021.
What does MAIA Biotechnology do?
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend..
Where is MAIA Biotechnology based and how big is it?
MAIA Biotechnology is based in Chicago, Illinois, United States.
Who are the decision-makers at MAIA Biotechnology?
Fundz holds 2 contacts at MAIA Biotechnology, including the Senior Director, Human Resources. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Medical around the same time

Companies in the same sectors as MAIA Biotechnology that raised within 45 days of this round, from Fundz verified event records.

  • OncoNano Medicine raised $50M (Series B) on June 17, 2021.
  • Camp4 Therapeutics Corp raised $45M (Funding Round) on June 15, 2021.
  • Immunome Inc. raised an undisclosed amount (Grant) on May 20, 2021.
  • Immunome Inc. raised $27M on May 11, 2021.
  • RetinalGeniX Technologies raised $45K (Pre-Seed) on July 1, 2021.
  • Julier Medical raised an undisclosed amount on June 30, 2021.

Who to call at MAIA Biotechnology, and when

A new round usually means MAIA Biotechnology is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day MAIA Biotechnology raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at MAIA Biotechnology, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at MAIA Biotechnology. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

MAIA Biotechnology

Location

Chicago, Illinois, United States

About

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment MAIA Biotechnology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsSean S., Senior Director, Human ResourcesSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for MAIA Biotechnology's next move

See what Strategic adds

MAIA Biotechnology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.